Tara Lynn Kieffer Sells 2,106 Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider owned 30,620 shares of the company’s stock, valued at $435,722.60. The trade was a 6.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Enanta Pharmaceuticals Trading Up 3.6%

Shares of Enanta Pharmaceuticals stock traded up $0.51 during trading on Friday, hitting $14.60. 333,749 shares of the stock traded hands, compared to its average volume of 400,542. The stock’s fifty day simple moving average is $11.89 and its 200 day simple moving average is $9.04. The firm has a market cap of $421.36 million, a P/E ratio of -3.81 and a beta of 0.96. Enanta Pharmaceuticals, Inc. has a 52-week low of $4.09 and a 52-week high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.26. The firm had revenue of $15.13 million for the quarter, compared to the consensus estimate of $15.60 million. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. As a group, equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its position in Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 1,383 shares during the period. AlphaQuest LLC raised its holdings in shares of Enanta Pharmaceuticals by 18.1% during the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 1,562 shares during the last quarter. Sio Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 1.0% during the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock worth $1,352,000 after purchasing an additional 1,770 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Enanta Pharmaceuticals by 13.4% during the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after purchasing an additional 1,940 shares during the period. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ENTA. Evercore ISI decreased their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday, September 15th. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the stock from $14.00 to $20.00 in a research report on Wednesday, October 1st. JPMorgan Chase & Co. began coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price objective for the company. JMP Securities boosted their target price on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 12th. Finally, Westpark Capital increased their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.